Long-acting octreotide for acromegaly
Part of Hormones & metabolism clinical trials.
This trial tests a long-acting form of octreotide, a medicine that lowers growth hormone levels, in people with active acromegaly. It aims to see if this treatment is safe and effective in controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with acromegaly that is still active, meaning your growth hormone and IGF-1 levels are too high.
- You have not had radiation therapy to the pituitary gland in the last 5 years.
- You have not had major surgery (including pituitary surgery) in the last 6 months, and you don't plan to have surgery or radiation during the study.
- You have not taken certain acromegaly medications recently, like long-acting lanreotide, long-acting octreotide, pegvisomant, cabergoline, or certain traditional Chinese medicines, within the last 3 months; bromocriptine within the last month; or short-acting octreotide or lanreotide within the last 7 days.
- You have not previously failed to respond to octreotide or lanreotide treatment, and you are not intolerant to them.
- You do not have serious vision problems caused by pressure on the optic nerve that require surgery.
- Your blood sugar control is stable, with an HbA1c level of 8.5% or lower.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
This trial tests if a ketogenic (very low-carb) diet can help lower IGF-I levels in people with acromegaly who are already on stable medication. If you have acromegaly and your IGF-I levels are still above normal despite treatment, this diet might offer an additional way to manage your condition.
Hear when a new Diagnosed With Acromegaly, Currently in the Active Stage of the Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.